Prospective evaluation of a 675-nm laser for facial rejuvenation in Fitzpatrick skin types III–V
4
Issued Date
2026-12-01
Resource Type
ISSN
03403696
eISSN
1432069X
Scopus ID
2-s2.0-105035120493
Journal Title
Archives of Dermatological Research
Volume
318
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Archives of Dermatological Research Vol.318 No.1 (2026)
Suggested Citation
Thaitirarot S., Nokdhes Y., Thongcharoensirikul P., Bhorntarakcharoen W., Sittiwanaruk S., Li J.B., Manuskiatti W. Prospective evaluation of a 675-nm laser for facial rejuvenation in Fitzpatrick skin types III–V. Archives of Dermatological Research Vol.318 No.1 (2026). doi:10.1007/s00403-026-04602-x Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/116167
Title
Prospective evaluation of a 675-nm laser for facial rejuvenation in Fitzpatrick skin types III–V
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
The 675-nm fractional, non-ablative laser has emerged as a promising modality for facial rejuvenation; however, evidence in darker skin phototypes remains limited. This prospective study evaluated the efficacy and safety of a 675-nm laser for facial photorejuvenation in individuals with Fitzpatrick skin types (FSTs) III–V. Twenty participants with mild-to-moderate photoaging underwent three monthly treatment sessions using sequential Moveo and Standard modes. Outcomes were assessed at baseline and at 1, 3, and 6 months after the final treatment using three-dimensional skin analysis with the Antera<sup>®</sup> system, skin elasticity measurements with the Cutometer<sup>®</sup>, blinded photographic evaluations using the Modified Fitzpatrick Wrinkle Scale (MFWS) and Global Subjective Skin-Aging Assessment (GS2A2), and patient- and physician- reported satisfaction scores. Safety and pain were recorded at each treatment session. The wrinkle indentation index showed a significant reduction at 6 months compared with baseline (p = 0.0101). Pigmentation values decreased significantly at 1 month (p = 0.0015) and remained reduced at 3 and 6 months (p = 0.045 and p = 0.0156, respectively). Gross elasticity (R2) and net elasticity (R5) increased significantly from 1 month after the first treatment and remained elevated through the 6-month follow-up (all p < 0.05). Blinded assessments demonstrated mean MFWS score reductions of 25%, 31%, and 31% at 1, 3, and 6 months after treatment, respectively (all p < 0.001), accompanied by significant improvements in GS2A2 scores. Patient-reported satisfaction increased progressively, with more than 70% of participants reporting at least 50% improvement by the third treatment session, sustained through 6 months. Physician global assessments paralleled these findings, with more than 80% of participants graded as having at least 50% improvement at the final follow-up. Treatments were well-tolerated, with minimal pain (visual analogue scale: 0.25 ± 0.86 for Moveo mode and 1.83 ± 1.95 for Standard mode). No cases of postinflammatory hyperpigmentation (PIH) or long-term adverse events were observed within the study cohort during the follow-up period. These findings suggest that fractional non-ablative 675-nm laser treatment is associated with significant and sustained improvements in wrinkles, skin elasticity, and pigmentation in individuals with FSTs III–V, with minimal downtime or favorable safety profile. Trial registration: Thai Clinical Trials Registry: TCTR20250123001; Registration date: 14 January 2024.